Instil Bio, Inc.

NASDAQ:TIL

Biotechnology

Healthcare
$7.45 +0.13%

+$0.01 today

Market cap
$50.53M
Beta
1.91
P/E (TTM)
-1.1
EPS (TTM)
-$6.99
52W Low $5.67High $33.83

Volume 0.02M

Average 0.03M

TIL Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Instil Bio, Inc.NASDAQ: TIL

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $0.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How TIL compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
TIL Competitors
Revenue for TIL and competitors
Company Period LTM YoY 3-year CAGR
MGNXMacroGenics, Inc.LTM Mar 2026$157.08M USD+3.1%-0.1%
SRZNSurrozen, Inc.LTM Mar 2026$7.49M USD-35.6%-34.7%
STTKShattuck Labs, Inc.LTM Mar 2026$1M USD-78.3%+15.3%
IFRXInflaRx N.V.LTM Mar 2026€29.33K EUR-77.4%—
TILInstil Bio, Inc.LTM Mar 2026$0 USD——
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$0 USD-100.0%—
WHWKWhitehawk Therapeutics IncLTM Mar 2026$0 USD-100.0%-22.3%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$0 CAD——
PLRXPliant Therapeutics, Inc.LTM Mar 2026$0 USD——
Peer median (excluding TIL) —-77.8%-11.2%

Competitors are the stored peer set for TIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue05.99M00534K
Gross Profit0(5.99M)00(534K)
Gross Margin—————
Research & Development107.25M141.06M39.6M11.84M10M
Selling, General & Admin51.31M62.24M47.55M44.21M27.22M
Operating Expenses155.56M200.18M159.17M73.54M52.37M
Depreciation & Amortization2.75M5.99M4.76M3.61M534K
EBITDA(152.51M)(217.38M)(147.12M)(62.53M)(65.01M)
EBITDA Margin—————
Operating Income(155.56M)(206.17M)(159.17M)(73.54M)(52.91M)
Operating Margin—————
Interest Income80K3.66M8.87M6.99M3.86M
Interest Expense01.88M5.21M8.99M5.83M
Other Income / Expenses(1.2M)(19.08M)3.08M(594K)(18.47M)
Income Before Tax(156.76M)(225.25M)(156.09M)(74.14M)(71.37M)
Pre-Tax Margin—————
Income Tax Expense39K(2.07M)000
Net Income(156.79M)(223.18M)(156.09M)(74.14M)(71.37M)
Net Margin—————
EPS (Basic)(29.60)(34.46)(24.00)(11.39)(10.70)
EPS (Diluted)(29.60)(34.46)(24.00)(11.39)(10.70)
Weighted Avg Shares5.3M6.48M6.5M6.51M6.67M
Weighted Avg Shares (Diluted)5.3M6.48M6.5M6.51M6.67M

Instil Bio, Inc.

NASDAQ:TIL

Intrinsic Alpha fair value

Locked

Current Price

$7.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.